Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

VCA Clinical Fellowship awarded for epithelial ovarian cancer research

Dr Clare Scott from the Walter and Eliza Hall Institute in Melbourne, Australia, has been awarded a Victorian Cancer Agency (VCA) Clinical Fellowship to further research into an aggressive and highly lethal form of ovarian cancer.

27 Oct 2010

Myriad signs agreement with Abbott for BRACAnalysis test

Myriad Genetics, Inc. today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer.

27 Oct 2010

ACOG joins Jay Monahan Center to develop new chapter on Female Cancers resource guide

The New York State Chapter of the American Congress of Obstetricians and Gynecologists, District II (ACOG) has partnered with the Jay Monahan Center for Gastrointestinal Health at NewYork-Presbyterian Hospital/Weill Cornell Medical Center to develop the fifth and final chapter to the Focus on Female Cancers resource guide.

22 Oct 2010

Matrix-Bio's VeraMarker-BCR blood test predicts breast cancer recurrence 13 months before clinical diagnosis

Connie Krabbe understands the fear and foreboding breast cancer survivors feel when visiting their physicians for post-treatment check-ups. Two of her four sisters died of metastatic cancer related to breast cancer, enduring bone, brain, and ovarian cancer before succumbing to the disease in their early 50s.

21 Oct 2010

Menopausal estrogen replacement therapy speeds growth of ovarian cancer

Estrogen therapy used by menopausal women causes a type of ovarian cancer to grow five times faster, according to a new study by researchers at the University of Colorado Cancer Center.

21 Oct 2010

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company's proprietary oral delivery technology.

21 Oct 2010

A universal cancer treatment for a universal cancer marker

A latest study shows that a hormone receptor normally confined to the reproductive organs is found in malignant tumors in many parts of the body. Researchers from the Mt. Sinai School of Medicine in New York City explained that this may mean a new target for the early diagnosis and treatment of cancer. The study was published in the latest issue of The New England Journal of Medicine.

20 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

MabCure announces agreement with Europe's medical centers to explore diagnostic test for ovarian cancer

Biotechnology company MabCure, Inc. today announced that it has signed a collaboration agreement with Catholic University, K.U. Leuven and University Hospital, UZ Leuven, Belgium, together comprising one of the largest and most reputable medical centers in Europe.

20 Oct 2010

Researchers to test nanoparticle-based theranostics for pancreatic cancer treatment

Researchers from Rice University's Laboratory for Nanophotonics (LANP), the radiology department at Baylor College of Medicine (BCM) and the University of Texas MD Anderson Cancer Center are preparing to test a combined approach for diagnosing and treating pancreatic cancer with a specially engineered nanoparticle.

19 Oct 2010

St. Joseph's gynecologic oncologist expresses concern about ovarian cancer study

An internationally-recognized gynecologic oncologist at St. Joseph's Hospital and Medical Center in Phoenix, Arizona is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously.

18 Oct 2010

Access receives first MuGard prescriptions and reimbursement

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.

15 Oct 2010

EntreMed receives letter from NASDAQ Stock Market

EntreMed, Inc. a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced that it has received a letter from the NASDAQ Stock Market indicating that it has regained compliance with the minimum $35 million Market Value of Listed Securities requirement for continued listing on the NASDAQ Capital Market as set forth in NASDAQ Marketplace Rule 5550(b)(2).

15 Oct 2010

Combination therapy for ovarian cancer leads to greater toxicity

Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity, according to a study published online October 11 in the Journal of the National Cancer Institute.

12 Oct 2010

Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer

Early results from a large Phase-III trial suggest that adding bevacizumab to chemotherapy as a treatment for newly diagnosed ovarian cancer reduces the risk of disease progression during the first year of treatment. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Tim Perren from Leeds Teaching Hospitals NHS Trust, UK, reported findings from the international ICON7 trial, which included 1528 women with high-risk early or advanced stage epithelial ovarian cancer, primary peritoneal cancer or Fallopian tube cancer.

11 Oct 2010

Access highlights clinical benefits of MuGard at ESMO conference

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy.

11 Oct 2010

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).

11 Oct 2010

OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress

OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.

11 Oct 2010

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's lorvotuzumab mertansine (IMGN901) targeted anticancer compound at the 35th European Society for Medical Oncology (ESMO) Conference being held in Milan, Italy, October 8-12, 2010.

11 Oct 2010

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

VCA Clinical Fellowship awarded for epithelial ovarian cancer research

Myriad signs agreement with Abbott for BRACAnalysis test

ACOG joins Jay Monahan Center to develop new chapter on Female Cancers resource guide

Matrix-Bio's VeraMarker-BCR blood test predicts breast cancer recurrence 13 months before clinical diagnosis

Menopausal estrogen replacement therapy speeds growth of ovarian cancer

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

A universal cancer treatment for a universal cancer marker

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

MabCure announces agreement with Europe's medical centers to explore diagnostic test for ovarian cancer

Researchers to test nanoparticle-based theranostics for pancreatic cancer treatment

St. Joseph's gynecologic oncologist expresses concern about ovarian cancer study

Access receives first MuGard prescriptions and reimbursement

EntreMed receives letter from NASDAQ Stock Market

Combination therapy for ovarian cancer leads to greater toxicity

Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer

Access highlights clinical benefits of MuGard at ESMO conference

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in